Impact of Hydroxymethylglutaryl Coenzyme A Reductase Inhibition on Left Ventricular Remodeling in Patients With Acute Anterior Myocardial Infarction After Primary Coronary Angioplasty

Hydroxymethyglutaryl coenzyme A reductase inhibition (statin) therapy has been shown to reduce cardiac hypertrophy in vitro and in vivo. We assessed the influence of short-term statin therapy on left ventricular (LV) remodeling after acute myocardial in-farction. Thirty-five patients with first anterior acute myocardial infarction, who underwent primary coronary angioplasty within 12 hours of onset, were divided into 2 groups. Ten patients taking statin served as the statin group, and 25 patients not taking statin served as the control group. Two-dimensional echocardiography was recorded after angioplasty (baseline) and at 4 weeks. LV ejection fraction (LVEF) at baseline was not significantly different between the 2 groups. However, the statin group had a higher LVEF at 4 weeks than the control group (58.2 +/- 5.0 versus 49.0 +/- 12.7%; P < 0.05). Moreover, the increase in LV end-diastolic volume (LVEDV) at 4 weeks was lower in the statin group than in the control group (12.1 +/- 29.6 versus 39.9 +/- 35.7 mL; P < 0.05). Multiple regression analysis demonstrated that administration of statin was an independent factor for the increase in LVEDV (P < 0.05). These findings indicate that short-term statin therapy can prevent postinfarct LV remodeling and improve LV function.